{
    "ticker": "LIXTW",
    "name": "Lixte Biotechnology Holdings, Inc.",
    "description": "Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapies. Founded in 2008, Lixte is focused on leveraging its proprietary technology to create new drug candidates that target critical pathways in cancer cell biology. The company's lead product candidate, LB-100, is a unique and promising drug that has shown potential in preclinical studies to enhance the efficacy of existing chemotherapy treatments and to function as a stand-alone therapy in various cancer models. Lixte aims to address significant unmet medical needs in oncology by developing therapies that can improve patient outcomes and quality of life. The company is actively engaged in clinical trials to evaluate the safety and effectiveness of its product candidates, and it collaborates with leading research institutions and cancer centers to advance its pipeline. Lixte's commitment to innovation in cancer treatment is underscored by its focus on identifying biomarkers that can predict patient response to therapy, thereby personalizing treatment regimens. With a team of experienced professionals in drug development, Lixte is positioned to make significant contributions to the field of oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "East Setauket, New York, USA",
    "founded": "2008",
    "website": "http://www.lixte.com",
    "ceo": "John S. Kovach",
    "social_media": {
        "twitter": "https://twitter.com/LixteBio",
        "linkedin": "https://www.linkedin.com/company/lixte-biotechnology-holdings-inc/"
    },
    "investor_relations": "http://www.lixte.com/investor-relations",
    "key_executives": [
        {
            "name": "John S. Kovach",
            "position": "CEO"
        },
        {
            "name": "David A. Pincus",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapies",
            "products": [
                "LB-100"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lixte Biotechnology Holdings, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer treatment. Learn about our innovative approaches and pipeline.",
        "keywords": [
            "Lixte Biotechnology",
            "Cancer Therapy",
            "LB-100",
            "Biopharmaceuticals",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What does Lixte Biotechnology do?",
            "answer": "Lixte Biotechnology is focused on the discovery and development of novel cancer therapies."
        },
        {
            "question": "What is LB-100?",
            "answer": "LB-100 is Lixte's lead product candidate, which has shown promise in enhancing chemotherapy efficacy and treating various cancers."
        },
        {
            "question": "Where is Lixte headquartered?",
            "answer": "Lixte is headquartered in East Setauket, New York, USA."
        },
        {
            "question": "When was Lixte founded?",
            "answer": "Lixte was founded in 2008."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "MRNA",
        "CLVS"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "JNJ",
        "PFE"
    ]
}